Literature DB >> 32815034

Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.

Margaretha A van der Slot1,2, Eva Hollemans3, Michael A den Bakker4,5, Robert Hoedemaeker6, Mike Kliffen4,5, Leo M Budel4,5, Natascha N T Goemaere4,5, Geert J L H van Leenders3.   

Abstract

The Grade group is an important parameter for clinical decision-making in prostate cancer. Recently, percent Gleason pattern 4 and presence of invasive cribriform and/or intraductal carcinoma (CR/IDC) have been recognized for their independent predictive value for prostate cancer outcome. There is sparse data on the inter-observer agreement for these pathologic features in practice. Our objectives were to investigate inter-observer variability of percent Gleason pattern and CR/IDC and to relate individual tumour scores to clinical outcome. Our cohort included 80 consecutive radical prostatectomies with a median follow-up 87.1 months (interquartile range 43.3-119.2), of which the slide with largest tumour volume was scored by six pathologists for Grade group (four tiers: 1, 2, 3 and 4/5), percent Gleason pattern 4 (four tiers: 0-25%, 26-50%, 51-75% and 76-100%) and presence of CR/IDC (two tiers: absent, present). The individual assignments were related to post-operative biochemical recurrence (20/80). Inter-observer agreement was substantial (Krippendorff's α 0.626) for assessment of Grade group and moderate for CR/IDC (α 0.507) and percent Gleason pattern 4 (α 0.551). For each individual pathologist, biochemical recurrence rates incremented by Grade group and presence of CR/IDC, although such relation was less clear for percent Gleason pattern 4. In conclusion, inter-observer agreement for CR/IDC and percent Gleason pattern 4 is lower than for Grade groups, indicating awareness of these features needs further improvement. Grade group and CR/IDC, but not percent Gleason pattern 4 was related to biochemical recurrence for each pathologist, indicating overall validity of individual grade assignments despite inter-observer variability.

Entities:  

Keywords:  Cribriform; Grade group; Inter-observer variability; Intraductal; Prostate cancer

Mesh:

Year:  2020        PMID: 32815034      PMCID: PMC7969485          DOI: 10.1007/s00428-020-02902-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  1 in total

1.  Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens.

Authors:  Axel Glaessgen; Hans Hamberg; Carl-Gustaf Pihl; Birgitta Sundelin; Bo Nilsson; Lars Egevad
Journal:  Virchows Arch       Date:  2004-05-20       Impact factor: 4.064

  1 in total
  4 in total

1.  Predicting biochemical recurrence of prostate cancer with artificial intelligence.

Authors:  Hans Pinckaers; Jolique van Ipenburg; Jonathan Melamed; Angelo De Marzo; Elizabeth A Platz; Bram van Ginneken; Jeroen van der Laak; Geert Litjens
Journal:  Commun Med (Lond)       Date:  2022-06-08

Review 2.  Cultivating Clinical Clarity through Computer Vision: A Current Perspective on Whole Slide Imaging and Artificial Intelligence.

Authors:  Ankush U Patel; Nada Shaker; Sambit Mohanty; Shivani Sharma; Shivam Gangal; Catarina Eloy; Anil V Parwani
Journal:  Diagnostics (Basel)       Date:  2022-07-22

3.  Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.

Authors:  Neslisah Seyrek; Eva Hollemans; Susanne Osanto; Rob C M Pelger; Henk G van der Poel; Elise Bekers; Chris H Bangma; John Rietbergen; Monique J Roobol; Ivo G Schoots; Geert J L H van Leenders
Journal:  Histopathology       Date:  2021-12-14       Impact factor: 7.778

Review 4.  WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.

Authors:  James G Kench; Mahul B Amin; Daniel M Berney; Eva M Compérat; Ian A Cree; Anthony J Gill; Arndt Hartmann; Santosh Menon; Holger Moch; George J Netto; Maria R Raspollini; Mark A Rubin; Puay Hoon Tan; Toyonori Tsuzuki; Samra Turjalic; Theo H van der Kwast; Ming Zhou; John R Srigley
Journal:  Histopathology       Date:  2022-08-02       Impact factor: 7.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.